Advertisement

Impella®: an updated meta-analysis of available data and future outlook on applications in cardiogenic shock

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Fig. 1

References

  1. 1.

    Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardiogenic shock. Eur Heart J. 2014;35(3):156–67.

  2. 2.

    Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382(9905):1638–45.

  3. 3.

    Ouweneel DM, de Brabander J, Karami M, Sjauw KD, Engstrom AE, Vis MM et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. Eur Heart J Acute Cardiovasc Care. 2019;8(4):338–49.

  4. 4.

    Jensen PB, Kann SH, Veien KT, Moller-Helgestad OK, Dahl JS, Rud CS, et al. Single-centre experience with the Impella CP, 5.0 and RP in 109 consecutive patients with profound cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2018;7(1):53–61.

  5. 5.

    Remmelink M, Sjauw KD, Henriques JP, de Winter RJ, Koch KT, van der Schaaf RJ, et al. Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheter Cardiovasc Interv. 2007;70(4):532–7.

  6. 6.

    Markus B, Patsalis N, Chatzis G, Luesebrink U, Ahrens H, Schieffer B, et al. Impact of microaxillar mechanical left ventricular support on renal resistive index in patients with cardiogenic shock after myocardial infarction: a pilot trial to predict renal organ dysfunction in cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2019; https://doi.org/10.1177/2048872619860218.

  7. 7.

    Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584–8.

  8. 8.

    Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(3):278–87.

  9. 9.

    Wernly B, Seelmaier C, Leistner D, Stahli BE, Pretsch I, Lichtenauer M et al. Mechanical circulatory support with Impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock‑a critical appraisal of current data. Clin Res Cardiol. 2019. https://doi.org/10.1007/s00392-019-01458-2.

  10. 10.

    DerSimonianab R, Lairdab N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. https://doi.org/10.1016/0197-2456(86)90046-2.

  11. 11.

    Karatolios K, Chatzis G, Markus B, Luesebrink U, Ahrens H, Dersch W et al. Impella support compared to medical treatment for post-cardiac arrest shock after out of hospital cardiac arrest. Resuscitation. 2018;126:104–10.

  12. 12.

    Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139(10):1249–58.

  13. 13.

    Alushi B, Douedari A, Froehlig G, Knie W, Wurster TH, Leistner DM et al. Impella versus IABP in acute myocardial infarction complicated by cardiogenic shock. Open Heart. 2019;6(1):e987.

  14. 14.

    Flaherty MP, Khan AR, O’Neill WW. Early initiation of Impella in acute myocardial infarction complicated by cardiogenic shock improves survival: a meta-analysis. JACC Cardiovasc Interv. 2017;10(17):1805–6.

  15. 15.

    Loehn T, O’Neill WW, Lange B, Pfluecke C, Schweigler T, Mierke J et al. Long term survival after early unloading with Impella CP((R)) in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2018. https://doi.org/10.1177/2048872618815063.

  16. 16.

    Esposito ML, Zhang Y, Qiao X, Reyelt L, Paruchuri V, Schnitzler GR et al. Left ventricular unloading before reperfusion promotes functional recovery after acute myocardial infarction. J Am Coll Cardiol. 2018;72(5):501–14.

  17. 17.

    Kapur NK, Alkhouli MA, DeMartini TJ, Faraz H, George ZH, Goodwin MJ et al. Unloading the left ventricle before reperfusion in patients with anterior ST-segment-elevation myocardial infarction. Circulation. 2019;139(3):337–46.

  18. 18.

    Udesen NJ, Moller JE, Lindholm MG, Eiskjaer H, Schafer A, Werner N et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J. 2019;214:60–8.

  19. 19.

    Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand WK, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42(12):1922–34.

  20. 20.

    Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671–83.

  21. 21.

    Jentzer JC, van Diepen S, Barsness GW, Henry TD, Menon V, Rihal CS, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol. 2019. https://doi.org/10.1016/j.jacc.2019.07.077.

  22. 22.

    Masyuk M, Wernly B, Lichtenauer M, Franz M, Kabisch B, Muessig JM et al. Prognostic relevance of serum lactate kinetics in critically ill patients. Intensive Care Med. 2019;45(1):55–61.

Download references

Author information

Correspondence to Christian Jung.

Ethics declarations

Conflict of interest

C. Jung reports grants, personal fees and non-financial support from Actelion, grants and personal fees from Bayer Healthcare, Vifor Pharma, Zoll Medical, personal fees from Pfizer, personal fees from Bristol Meyer Squibb, personal fees and non-financial support from Abbott Vascular, personal fees from Boston Scientific, personal fees from Boehringer Ingelheim, personal fees from Sanofi Aventis, grants, personal fees and non-financial support from Novartis, grants from Medicure Inc., personal fees and non-financial support from Orion Pharma, outside the submitted work. B. Wernly, A. Lauten and H. Thiele declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors. All procedures reported in this article were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wernly, B., Lauten, A., Thiele, H. et al. Impella®: an updated meta-analysis of available data and future outlook on applications in cardiogenic shock. Wien Klin Wochenschr (2020) doi:10.1007/s00508-019-01600-0

Download citation